A Prospective Observational Analysis Comparing the Safety and Effectiveness of Beta Blockers in Heart Failure with Preserved Ejection Fraction (HFPEF) To Those with Heart Failure with Reduced Ejection Fraction (HFREF)
DOI:
https://doi.org/10.53555/AJBR.v28i3S.7332Keywords:
HFpEF, HFrEF, Bisoprolol, Metoprolol, Carvedilol, Nebivolol.Abstract
Aim: To compare the effectiveness and safety of beta blockers in heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) patients.
Methods: A six-month prospective study at Aware Gleneagles Hospital, Hyderabad, enrolled 100 patients (50 HFpEF, 50 HFrEF). Demographic data, clinical parameters, and medication use were collected and analyzed. Primary endpoints: vital signs, adverse events, and duration of hospital stay. Secondary outcomes: reduction in NT-proBNP, renal impairment, and drug interactions. Statistical analyses: t-tests, chi-square tests, and survival analysis.
Results: Bisoprolol showed maximum efficacy, decreasing NT-proBNP by 22% (HFpEF) and 30% (HFrEF), with lesser side effects and shorter hospitalizations (5.6 ± 1.8 days) compared to Metoprolol, Carvedilol, and Nebivolol.
Conclusion: Bisoprolol is the most efficacious beta blocker for HFpEF and HFrEF patients, enhancing outcomes and reducing side effects.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dr. sumera iram, Mohd jawaduddin, Dinesh kumar, Prince Tiwari (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.



